Marwa Elsayed Elnaggar, Ali Ali Okab, Mohammed Hussein Kamel, Amira Mohammed Noureldin, Doaa Adel Abdelhafez, Maha Mammdouh Osman
{"title":"将慢性阻塞性肺病患者体内的透明质酸作为预后生物标志物进行评估","authors":"Marwa Elsayed Elnaggar, Ali Ali Okab, Mohammed Hussein Kamel, Amira Mohammed Noureldin, Doaa Adel Abdelhafez, Maha Mammdouh Osman","doi":"10.1186/s43168-024-00276-z","DOIUrl":null,"url":null,"abstract":"One essential element of the extracellular matrix is hyaluronic acid (HA). It has been claimed that HA and its metabolism are different in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study investigated the predictive significance of serum level of HA in patients with COPD and monitored changes in its level in these patients because of therapy. HA was assessed in 60 patients with stable COPD (divided into subgroups I and II) and 20 healthy controls and then repeated after 3 and 6 months in COPD patients. Most of the patients were males (63.3%), and their ages ranged from 30 to 90. The serum level of HA was significantly increased in subgroups I and II (269.33 ± 4, 290 ± 4, respectively), compared to the control group (147.5 ± 1) with a significant difference in its level between both (p < 0.0001). The serum level of HA was significantly decreased in both subgroups 3 and 6 months later following adjustment of treatment and associated with improvement in pulmonary function test. There were significant positive correlations between HA and age as well as smoking index. Its level correlated negatively with forced expiratory volume in the first second (FEV1%), forced vital capacity (FVC%), and FEV1/FVC. HA is a useful marker for identifying clinical stability in COPD patients and for follow-up in the efficacy of treatment.","PeriodicalId":22426,"journal":{"name":"The Egyptian Journal of Bronchology","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of hyaluronic acid in COPD patients as a prognostic biomarker\",\"authors\":\"Marwa Elsayed Elnaggar, Ali Ali Okab, Mohammed Hussein Kamel, Amira Mohammed Noureldin, Doaa Adel Abdelhafez, Maha Mammdouh Osman\",\"doi\":\"10.1186/s43168-024-00276-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"One essential element of the extracellular matrix is hyaluronic acid (HA). It has been claimed that HA and its metabolism are different in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study investigated the predictive significance of serum level of HA in patients with COPD and monitored changes in its level in these patients because of therapy. HA was assessed in 60 patients with stable COPD (divided into subgroups I and II) and 20 healthy controls and then repeated after 3 and 6 months in COPD patients. Most of the patients were males (63.3%), and their ages ranged from 30 to 90. The serum level of HA was significantly increased in subgroups I and II (269.33 ± 4, 290 ± 4, respectively), compared to the control group (147.5 ± 1) with a significant difference in its level between both (p < 0.0001). The serum level of HA was significantly decreased in both subgroups 3 and 6 months later following adjustment of treatment and associated with improvement in pulmonary function test. There were significant positive correlations between HA and age as well as smoking index. Its level correlated negatively with forced expiratory volume in the first second (FEV1%), forced vital capacity (FVC%), and FEV1/FVC. HA is a useful marker for identifying clinical stability in COPD patients and for follow-up in the efficacy of treatment.\",\"PeriodicalId\":22426,\"journal\":{\"name\":\"The Egyptian Journal of Bronchology\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Egyptian Journal of Bronchology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s43168-024-00276-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian Journal of Bronchology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43168-024-00276-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
透明质酸(HA)是细胞外基质的重要元素之一。有研究称,慢性阻塞性肺病(COPD)患者肺部的透明质酸及其代谢与正常人不同。本研究调查了慢性阻塞性肺病患者血清中 HA 水平的预测意义,并监测了这些患者在治疗过程中 HA 水平的变化。研究人员对 60 名慢性阻塞性肺病稳定期患者(分为 I 组和 II 组)和 20 名健康对照者进行了 HA 评估,并在 3 个月和 6 个月后对慢性阻塞性肺病患者进行了重复评估。大部分患者为男性(63.3%),年龄在 30 至 90 岁之间。与对照组(147.5 ± 1)相比,I 组和 II 组患者的血清 HA 水平明显升高(分别为 269.33 ± 4 和 290 ± 4),且两者之间存在显著差异(P < 0.0001)。调整治疗 3 个月和 6 个月后,两个亚组的血清 HA 水平均明显下降,且与肺功能测试的改善相关。HA 与年龄和吸烟指数呈明显的正相关。其水平与第一秒用力呼气容积(FEV1%)、用力肺活量(FVC%)和 FEV1/FVC 呈负相关。HA 是识别慢性阻塞性肺病患者临床稳定性和跟踪治疗效果的有用指标。
Assessment of hyaluronic acid in COPD patients as a prognostic biomarker
One essential element of the extracellular matrix is hyaluronic acid (HA). It has been claimed that HA and its metabolism are different in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study investigated the predictive significance of serum level of HA in patients with COPD and monitored changes in its level in these patients because of therapy. HA was assessed in 60 patients with stable COPD (divided into subgroups I and II) and 20 healthy controls and then repeated after 3 and 6 months in COPD patients. Most of the patients were males (63.3%), and their ages ranged from 30 to 90. The serum level of HA was significantly increased in subgroups I and II (269.33 ± 4, 290 ± 4, respectively), compared to the control group (147.5 ± 1) with a significant difference in its level between both (p < 0.0001). The serum level of HA was significantly decreased in both subgroups 3 and 6 months later following adjustment of treatment and associated with improvement in pulmonary function test. There were significant positive correlations between HA and age as well as smoking index. Its level correlated negatively with forced expiratory volume in the first second (FEV1%), forced vital capacity (FVC%), and FEV1/FVC. HA is a useful marker for identifying clinical stability in COPD patients and for follow-up in the efficacy of treatment.